Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Immutep Limited (NASDAQ: IMMP) has announced final overall survival data (OS) from its Phase 2b AIPAC trial. 227 patients with HER2-negative/HR-positive metastatic breast cancer (HR+ MBC) were 1:1 randomized in the AIPAC study.

Immutep's Lead Candidate Data In Breast Cancer Trial Fails To Lift The Stock

SYDNEY, AUSTRALIA, Nov. 10, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that data from its AIPAC, TACTI-002 and TACTI-003 studies have been published in abstracts available via the links below on the SITC 2021 Annual Meeting's official website or the Company's website.

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

SYDNEY, AUSTRALIA, Nov. 02, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL 201610221687) entitled “Use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response” by the Chinese Patent Office. The patent forms part of a broad and growing portfolio of patent families for the Company's lead product candidiate eftilagimod alpha (“efti” or “IMP321”) in key global markets including China.

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

SYDNEY, AUSTRALIA, Oct. 29, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it has received positive feedback from the European Medicines Agency (EMA) regarding its clinical development program for lead product candidate, eftilagimod alpha (efti), including the planned Phase III trial in MBC.

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

SYDNEY, AUSTRALIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti”) and IMP761 for the quarter ended 30 September 2021.

Immutep Quarterly Activities Report & Appendix 4C

SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €2,126,617 (~ A$3,430,952) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d'Impôt Recherche scheme (CIR).

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha (“efti” or “IMP321”) in metastatic breast cancer at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021. SITC 2021 is taking place in Washington, US and virtually from 10-14 November.

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 1 September 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces that the last patient has been enrolled and safely dosed in Stage 2 of Part B of its Phase II TACTI-002 study (also designated KEYNOTE-798). This completes the recruitment of 2nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patients into the trial.

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partner for eftilagimod alpha (“efti” or “IMP321”), EOC Pharma (“EOC”) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China.

Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201580013695.X entitled “Antibody molecules to LAG-3 and uses thereof” by the Chinese Patent Office.

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003. This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immutep's lead product candidate eftilagimod alpha (efti or IMP321).

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

Immutep Limited (NASDAQ: IMMP) has completed all the necessary steps with the FDA and has received institutional review board approval to commence its Phase 2b TACTI-003 trials in the U.S. Patient recruitment for the trial will begin in Q3 of 2021. It will evaluate the Company's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck Co & Inc's (NYSE: MRK) Keytruda (pembrolizumab) as first-line therapy in approximately 154 patients with Head and Neck Squamous Cell Carcinoma (HNSCC).

Immutep Shares Are Trading Higher On Green Signal To Start Efti Combo Trial In First-Line Head & Neck Cancer

Immutep (NASDAQ: IMMP) will begin a Phase 1 trial to evaluate its lead product candidate, eftilagimod alpha (efti or IMP321), in conjunction with chemotherapy and anti-PD-1 therapy. The trial, named INSIGHT-003, will be carried out at the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt, Germany.

Immutep To Initiate Efti Triple Combination Therapy Trial In Solid Tumors, Launches $60M Placement

Allied Esports Entertainment Inc

American Resources Corp

CTI BioPharma

Cenntro Electric Group

Super League Gaming Inc

Uranium Energy

Reddit penny stocks are full of risk and reward, which is why $100 won't hurt you, but it can reward you handsomely. The post 7 Reddit Penny Stocks to Buy if You Have $100 to Spare appeared first on InvestorPlace.

7 Reddit Penny Stocks to Buy if You Have $100 to Spare

SYDNEY, AUSTRALIA, June 04, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from its Phase II TACTI-002 study (also designated KEYNOTE-798) with a data cut-off date of 16 April 2021. The data will be presented in two poster presentations by Dr Tim Clay, Investigator, St John of God Subiaco Hospital, Perth, Australia and Dr Irene Brana, Investigator, Vall d'Hebron Institute of Oncology, Barcelona, Spain at the American Society of Clinical Oncology's (ASCO) 2021 Annual Meeting in on-demand sessions available from 9 am on 4 June 2021, US Eastern Time at this year's virtual conference. The posters will also be made available on Immutep's website from that time at:

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number EP3473263 entitled “Combined Preparations for the Treatment of Cancer” by the European Patent Office.

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

Merck KGaA

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors. The trial will evaluate the feasibility, safety, and efficacy of Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with bintrafusp alfa (M7824).

Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors

The stock price of Immutep Limited (NASDAQ: IMMP) increased by over 14% pre-market. This is why it happened.

IMMP Stock Price: Over 14% Increase Pre-Market Explanation

SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate in the Jefferies Virtual Healthcare Conference, which is taking place from June 1st to 4th.

Immutep To Present At The Jefferies Virtual Healthcare Conference

Immutep Limited (NASDAQ: IMMP) has announced that data from its TACTI-002 and INSIGHT-004 studies have been published in abstracts for the American Society of Clinical Oncology's 2021 Annual Meeting. Data from Phase I INSIGHT trial evaluating eftilagimod alpha combined with Pfizer Inc's (NYSE: PFE) Bavencio (avelumab) in advanced solid tumors showed: Five patients showed partial response (PR) as the best response, one stable disease with clinical progression (all but one of these patients are still alive).

Immutep Stock Gains on Encouraging Data from Early-Stage Solid Cancer Studies

Aehr Test Systems

Onconova Therapeutics

Uxin Ltd - ADR

Are these the top penny stocks to buy in 2021? Take a look and decide for yourself The post Top Penny Stocks to Buy Now?

Top Penny Stocks to Buy Now? 4 Big Movers to Watch Today

This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As clinical data continues to strengthen, Immutep is seemingly well situated for potential takeout or large biobucks deal(s).

Immutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or Takeout

Aikido Pharma Inc.

Actinium Pharmaceuticals

Atossa Genetics

Bionano Genomics

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.

7 Reddit Penny Stocks Promising to Cure Cancer

Sydney, AUSTRALIA, May 07, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on its clinical and preclinical programs.

Immutep Operational Update

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology's (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June.

News for Immutep Ltd Stock (IMMP)